Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.33 |
| ▸ | CFTR | P13569 | 4/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795974 | 0.85 | CYP2A6 (0.44) | CYP1A2CYP2A6NR4A2MAPTHTT | |
| SCHEMBL1295362 | 0.77 | MAPT (0.35) | HSP90AA1MAPTHTTGPR84CFTR | |
| SCHEMBL5800459 | 0.75 | CYP1A2 (0.48) | CYP1A2CYP2A6HSP90AA1MAPTHTT | |
| SCHEMBL1747611 | 0.75 | MAPT (0.46) | HSP90AA1MAPTHTTGPR84ALDH1A1 | |
| SCHEMBL30873742 | 0.75 | MAPT (0.46) | HSP90AA1MAPTHTTGPR84ALDH1A1 | |
| SCHEMBL1261956 | 0.75 | ALDH1A1 (0.48) | NR4A2HSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL12751165 | 0.75 | MAPT (0.34) | HSP90AA1MAPTHTT | |
| SCHEMBL4437293 | 0.75 | MAPT (0.42) | CYP1A2HSP90AA1MAPTHTTALDH1A1 | |
| SCHEMBL19135924 | 0.75 | CYP1A2 (0.48) | CYP1A2CYP2A6NR4A2CFTRALDH1A1 | |
| SCHEMBL7900240 | 0.74 | HTT (0.42) | HSP90AA1MAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941162-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-10-31 | — | — | US | disclosed |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919914-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CYP1A2 2099/4885CYP2A6 2986/4885NR4A2 3905/4885 |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | CYP1A2 1260/4885CYP2A6 2749/4885NR4A2 1392/4885 |
| US-20190135833-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP1A2 2099/4885CYP2A6 2986/4885NR4A2 3905/4885 |
| US-10941162-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CYP1A2 1439/4885CYP2A6 2373/4885NR4A2 2771/4885 |
| US-20190330240-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CYP1A2 2099/4885CYP2A6 2986/4885NR4A2 3905/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | CYP1A2 1206/4885CYP2A6 1680/4885NR4A2 3130/4885 |
| US-10253047-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | CYP1A2 1157/4885CYP2A6 2795/4885NR4A2 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.